Polycyclic heterocyclic compounds, a process for their preparation and their use in human and veterinary medicine

ABSTRACT

A polycyclic heterocyclic compound has the formula    &lt;IMAGE&gt;  (I) wherein n is 1 or 2, R1 l represents (i) lower alkyl, (ii) -CH2OH or (iii)   &lt;IMAGE&gt;  R2 represents (a) hydrogen, (b)   &lt;IMAGE&gt;   or (c)-OR3, R3 represents hydrogen, C1-C20 alkyl mono or polyhydroxyalkyl, aryl or aralkyl optionally substituted, the residue of a sugar or   &lt;IMAGE&gt;   wherein p is 1, 2, or 3, and r&#39; and r&#39;&#39; represent hydrogen, lower alkyl, mono or polyhydroxyalkyl, aryl optionally substituted, amino acid residue, aminated sugar residue, or together form a heterocycle, X represents oxygen, sulfur, SO, SO2 or -NR4, Y represents CR4 or a nitrogen atom and R4 represents hydrogen or lower alkyl. This polycyclic heterocyclic compound can be used in human and veterinary medicine and especially in the topical or systemic treatment of determatologic diseases.

BACKGROUND OF THE INVENTION

The present invention relates to polycyclic heterocyclic derivatives, toprocesses for their preparation and their use in human and veterinarymedicine and in cosmetic compositions.

These heterocyclic derivatives find use in the topical and systemictreatment of dermatologic diseases linked to a keratinization disorder(differentiation-proliferation) and dermatologic disorders, or others,having inflammatory and/or immunoallergic components and in thetreatment of conjunctive tissue degeneration illnesses. Thesederivatives also exhibit antitumoral activity. Moreover, thesederivatives can be employed in the treatment of atrophy, be it cutaneousor respiratory and in the treatment of rheumatoid psoriasis.

Lastly, they find use in the ophthalmologic field, principally in thetreatment of corneopathies.

The polycyclic heterocyclic derivatives in accordance with the presentinvention can be represented by the formula ##STR4## wherein n is 1 or2, R₁ represents (i) lower alkyl, (ii) --CH₂ OH or (iii) ##STR5## R₂represents (a) hydrogen, (b) ##STR6## or (c) --OR₃ wherein R₃ representshydrogen, alkyl having 1-20 carbon atoms, mono or polyhydroxyalkyl, arylor aralkyl optionally substituted or the residue of a sugar or ##STR7##wherein p is 1, 2 or 3, r' and r" represent hydrogen, lower alkyl,monohydroxyalkyl, polyhydroxyalkyl, aryl optionally substituted, aminoacid residue, aminated sugar residue or, taken together, form aheterocycle,

X represents oxygen, sulfur, SO, SO₂ or --NR₄,

Y represents CR₄ or a nitrogen atom, and

R₄ represents hydrogen or lower alkyl, and the salts of said polycyclicheterocyclic derivatives of formula I.

By alkyl having 1-20 carbon atoms is meant, principally, methyl, ethyl,propyl, 2-ethylhexyl, octyl, dodecyl, hexadecyl and octadecyl.

By lower alkyl is meant a radical having 1-4 carbon atoms andprincipally methyl, ethyl, isopropyl, butyl and tert.butyl.

By monohydroxyalkyl is meant a radical having 2-4 carbon atoms andprincipally 2-hydroxyethyl, 2-hydroxypropyl and 2'-hydroxy-2-ethoxyethyl.

By polyhydroxyalkyl is meant a radical containing 3-6 carbon atoms and2-5 hydroxyl groups such as 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl,2,3,4,5-tetrahydroxypentyl or the residue of pentaerythritol.

By residue of a sugar is meant a residue derived, for example, fromglucose, mannose, erythrose or galactose.

Representative aminated sugar residues include those derived fromglucosamine, galactosamine or mannosamine.

By aryl is meant phenyl optionally substituted by halogen, hydroxy, anitro function or lower alkyl.

Representative preferred aralkyls include, preferably, benzyl as well asphenethyl.

When r' and r" taken together form a heterocycle, the heterocycle can bepiperidino, piperazino, morpholino, pyrrolidino or 4-(2'-hydroxyethyl)piperazino.

When the compounds of the present invention are provided in the form ofsalts they can be salts of an alkali or alkaline earth metal or even ofzinc, or of an organic amine when they have at least one free acidfunction, or salts of a mineral or organic acid, principally,hydrochlorides, hydrobromides or citrates when they have at least oneamine function.

Representative compounds of formula I include, principally, thefollowing:

methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]furyl) benzoicacid,

p-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphtho[2,3-b]furyl)benzoic acid,

methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl) benzoicacid,

methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl) benzoicacid,

methyl ester ofp-(1-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-benz[f]indolyl)benzoic acid,

p-(1-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-benz[f]indolyl)benzoic acid,

methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzyl alcohol,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic aldehyde,

ethylamide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic

morpholide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid,

2-hydroxyethyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid,

methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]imidazolyl)benzoic acid,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]imidazolyl)benzoic acid and

2-(4-methyl)phenyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphth[2,3-d]imidazole.

Particularly preferred compounds of formula I in accordance with thepresent invention are those having the following formula: ##STR8##wherein

R₃ represents hydrogen or lower alkyl,

X represents oxygen, sulfur or NR₄,

Y represents CR₄ or a nitrogen atom, and

R₄ represents hydrogen or methyl.

Representative compounds corresponding to formula II include,principally:

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid and its methyl ester,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-1H-benz[f]indolyl) benzoicacid and its methyl ester,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid and its methyl ester,

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]imidazolyl)benzoicacid and its methyl ester, and

p-(1-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-benz[f]indolyl)benzoic acid and its methyl ester.

The present invention also relates to a process for the preparation ofthe compounds of formula I.

These compounds can be obtained in accordance with two synthesismethods:

(A) The First method (Scheme I)

This method is particularly preferred when, in the compounds of formulaI, Y represents a nitrogen atom.

This method comprises reacting an aromatic carboxylic acid derivative offormula (1) with an aromatic diamino, hydroxyamino or thioaminoderivative of formula (2). ##STR9##

The action of the acid chloride (1) (Q═Cl) on the aromatic aminocompound (2) leads to the intermediate (3') which is isolated. In thesame way, the coupling of the acid (1) (Q═OH) with the compound (2), inthe presence of triphenylphosphine and dicyclohexylcarbodiimide, ordiethylazodicarboxylate and triphenylphosphine, in a known manner, leadsto intermediate compounds (3').

This intermediate compound (3') is then cyclized by acid treatment togive compounds of formula (3). There can be employed for thiscyclization reaction a sulfonic acid such as p-toluene sulfonic acid inan inert solvent such as toluene or xylene. The cyclization reactiontemperature is preferably close to the reflux temperature of the solventemployed.

In accordance with a variation of this process, it is possible todirectly produce the compounds of formula (3) by direct heating of theacid of formula (1) (Q═OH) and the aromatic amino compound (2) in aninert solvent such as xylene in the presence of an acid catalyst; forexample, p-toluene sulfonic acid at the reflux temperature of thesolvent.

(B) Second method (Scheme II)

The method is quite particularly preferred when, in the compounds offormula I, Y represents CR₄. ##STR10##

In accordance with this second method, the cyclization reaction, thatis, the conversion of the derivative (7) having a phosphonium orphosphinyl group to compound (8) is effected in accordance with theWittig or Wittig-Horner reaction conditions, that is, in the presence ofa base which can be a hydroxide or carbonate of an alkali metal, forexample, lithium hydroxide or potassium carbonate, an alkali metalhydride, for example, sodium hydride, an alkali metal alcoholate, forexample, sodium methylate or potassium tert.butoxide, a tertiary amine,for example, triethylamine, di-isopropylethylamine ordiazabicycloundecene (DBU) or even an alkali amide, for example, sodiumamide or lithium di-isopropylamide. The reaction temperature is between-78° C. and +150° C. and there can be employed, as a dipolar aproticsolvent (dimethylsulfoxide or dimethylformamide), an alcohol, or anether (dioxane or tetrahydrofuran). The reaction is advantageouslycarried out in tetrahydrofuran (THF) at a temperature between 0° C. and80° C. using triethylamine or DBU as the base.

The bromination reaction, i.e., the production of the compound of theformula (6) is carried out in the presence of N-bromosuccinimide inpreviously dried benzene or carbon tetrachloride, the temperaturepreferably being between 70° C. and 90° C., the radical initiator being,preferably, benzoyl peroxide.

The acylation reaction, i.e., the production of the compound of formula(5) is carried out in a conventional manner. When X represents NH, thereaction is advantageously effected using the compound of formula (1) inthe form of an acid chloride (Q═Cl) in the presence of a tertiary amine.

The compounds produced in accordance with the two methods describedabove can be converted in accordance with conventional procedures toprovide compounds having any of the other meanings of R₁ set forthabove.

Thus, saponification of esters gives the corresponding acids which canthen be transformed into acid chlorides which are then easily convertedinto amides. These amides can also be obtained by the direct reaction ofamines with previously obtained esters. Reduction of esters, aldehyde oramide by an appropriate reducing agent (for example, lithium aluminumhydride) produces corresponding alcohols and amines.

The present invention also relates to, as novel industrial products,synthesis intermediates having the formula ##STR11## wherein

n is 1 or 2,

X represents oxygen, sulfur or NR₄, and

R₄ represents hydrogen or lower alkyl.

Representative intermediate compounds of formula III includeparticularly the following:

2,3-diamino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphthalene and

3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol.

The compounds of the present invention exhibit excellent activity in theinhibition test of ornithine decarboxylase in nude rats, afterinduction, by "tape stripping," M. Bouclier et al., Dermatologica, 169,No. 4, 1984. This test is recognized as a measure of the activity ofretinoides or cellular proliferation phenomena.

These compounds are particularly appropriate for treating dermatologicailments linked to a keratinization disorder(differentiation-proliferation) as well as dermatologic diseases havingan inflammatory and/or immunoallergic component, principally:

acne vulgaris, comedons or polymorphs, solar senile acne and medicinalor professional acne,

solar keratites,

extensive or severe forms of psoriasis, and other keratinizationdisorders and principally ichtysoses and ichtysosis like conditions,

Darier malady,

palmo-plantar keratodermies,

leucophasies and leucophasis-like states, lichen plane, and

all malignant or benign dermatologic proliferations, severe orextensive.

They are also active for certain rheumatoid disorders, in the treatmentof tumors, of rheumatoid psoriasis, cutaneous or respiratory atrophiesas well as in certain ophthalmoligic problems relating to corneopathies.

These compounds can also be employed to combat against ageing of theskin and in particular ageing due to the effects of the sun.

Thus the present invention also relates to medicinal compositionscontaining at least one compound of formula I, such as defined above, orone of its salts.

The present invention thus relates to a new medicinal composition,intended principally for the treatment of the above-mentioned disorders,comprising in a pharmaceutically acceptable support, an effective amountof at least one compound of formula I or one of its salts.

The compounds according to the present invention are generallyadministered at a daily dosage of about 0.01 μg/kg to 1 mg/kg of bodyweight.

As the vehicle or carrier for these compositions any conventionalvehicle can be employed, the active component being found either in thedissolved state, or in the dispersed state, in said vehicle.

The administration of the compounds of the present invention can beeffected enterally, parenterally, rectally, topically or ocularly.

When administered enterally, the medicines can be provided in the formof tablets, gelules, lozenges, syrups, suspensions, solutions, powders,granules or emulsions.

When administered parenterally, the medicinal compositions can beprovided in the form of solutions or suspensions for perfusion orinjection.

When administered rectally, the compositions can be provided in the formof suppositories.

When administered topically, the pharmaceutical compositions, based onthe compounds according to the present invention, can be provided in theform of ointments, tinctures, creams, salves, powders, pads, impregnatedtampons, solutions, lotions, gels, sprays or suspensions. Thecompositions for topical administeration contain preferably from0.000001 to about 0.01 percent by weight of the compound of formula I.These compositions for topical administration can be provided underanhydrous form or in aqueous form according to clinical indications.

When administered ocularly, the composition is provided principally inthe form of an eyewash.

The compounds of formula I, according to the present invention, are alsouseful in the cosmetic field, and n particular in body and hair hygienecompositions and principally for the treatment of skin having acnetendencies, to improve the growth of the hair, i.e., to promote thegrowth of existing hair folicles, to combat hair loss, to combat againstan oily appearance of the skin or hair, in the prevention or treatmentof the harmful effects of the sun or in the treatment of physiologicallydry skin.

The present invention thus relates to a cosmetic composition containing,in a cosmetically acceptable vehicle, an effective amount of at leastone compound of formula I or one of its salts, this composition beingprovided principally in the form of a lotion, gel, soap or shampoo.

The concentration of the compound of formula I in these cosmeticcompositions is between 0.00001 and 0.01 percent by weight based on thetotal weight of the composition.

The medicinal and cosmetic compositions according to the presentinvention can contain inert or even pharmacodynamic or cosmeticallyactive additives and, principally: hydrating agents such asthiamorpholinone and its derivatives or urea; antiseborrheic oranti-acne agents such as S-carboxymethylcysteine, S-benzylcysteamine,their salts and their derivatives, tioxolone or benzoyl peroxide;antibiotics such as erythromycin and its esters, neomycin, tetracyclinesor 4-polymethylene-4-isothiazoline-3-ones; agents promoting the growthof hair such as "Minoxidil" (2,4-diamino-6-piperidino-3-pyrimidineoxide) and its derivatives, Diazoxide(7-chloro-3-methyl-1,2,4-benzothiadiazine-1,1-dioxide) and Phenytoin(5,5-diphenyl-2,4-imidazolidine dione); steroidal and non-steroidalanti-inflammatory agents; carotenoids and, principally, β-carotene;anti-psoriasic agents such as anthralin and its derivatives and5,8,11,14-eicosatetraynoic and 5,8,11-eicosatriynoic acids, and theiresters and amides.

The compositions according to the present invention can also includeflavor improving agents, preservatives, stabilizers, humidity regulatingagents, pH regulating agents, osmotic pressure modifying agents,emulsifiers, anti-oxidants such as α-tocopherol, butylhydroxyanisole orbutylhydroxytoluene.

The following non-limiting examples illustrate the preparation of theactive compounds of formula I according to the present invention as wellas compositions containing these compounds.

Examples of Preparation EXAMPLE 1 Preparation of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]furanyl)benzoic acid (a)3-methyl-5,6,7,8-tetrahydro-5,5,8,8p-(5,6,7,8-tetramethyl-2-naphthol

Into a round bottom flask there are introduced 10.8 g (100 mmoles) ofortho cresol, 100 ml of dichloromethane (CH₂ Cl₂) and 18.3 g (100mmoles) of 2,4-dichloro-2,4-dimethylhexane. The reaction mixture iscooled to 5° C. and there are added, in small quantities, 6.6 g (50mmoles) of aluminum chloride. The temperature is permitted to rise to20° C. The reaction mixture is stirred for 2 hours and it is then pouredinto 200 ml of water. The organic phase is decanted, dried on magnesiumsulfate (MgSO₄) and the solvents are evaporated. The residue isrecrystallized in 100 ml of hexane, yielding 20.3 g (93%) of3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol which meltsat 122°-123° C.

(b) methyl ester ofp-(3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyloxycarbonyl) benzoic acid

In 100 ml of tetrahydrofuran (THF) there are disolved 8.7 g (40 mmoles)of the naphthol obtained in 1(a) above and 6.2 ml (44 mmoles) oftriethylamine. A solution of p-(methoxycarbonyl) benzoyl chloride (8.8g=44 mmoles) in THF (50 ml) is slowly added and the reaction mixture isstirred for 4 hours at ambient temperature. The reaction mixture ispoured into 200 ml of water and extracted with 300 ml of CH₂ Cl₂. Theorganic phase is decanted, dried on MgSO₄ and the solvents areevaporated. The residue is recrystallized in isooctane, yielding 11 g(72%) of the methyl ester ofp-(3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyloxycarbonyl) benzoic acid which melts at 111°-114° C.

(c) Methyl ester ofp-(3-bromomethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyloxycarbonyl) benzoic acid

A mixture of the ester obtained in 1(b) (10.60 g; 27.8 mmoles), benzoylperoxide (50 mg) and carbon tetrachloride (CCl₄), (150 ml) is brought toreflux. There are then added, in small quantities, 4.96 g (27.8 mmoles)of N-bromosuccinimide (NBS).

Reflux is maintained for 24 hours and the solvent is evaporated. Theresidue is purified by passage through a silica column (eluant: 1/1mixture of hexane/CH₂ Cl₂). 12 g of a mixture containing 80% of theexpected ester and 20% of the starting ester are recovered.

(d) Methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphtho[2,3-b]furanyl-2-yl)benzoic acid

In a round bottom flask, 11.8 g of the mixture obtained in 1(c), 100 mlof THF and 6.50 g (24.6 mmoles) of triphenylphosphine are introduced.The reaction mixture is heated at reflux for 4 hours and cooled to 10°C. There are then slowly added 3.70 ml (24.6 mmoles) of 1,8-diazabicyclo(5.4.0) undec-7-ene (DBU). The reaction mixture is permitted to returnto ambient temperature and it is stirred for 5 hours. The reactionmixture is then poured into water, extracted with ether, dried on MgSO₄and the solvents are evaporated.

The residue is purified by passage through a silica column (eluant: 1/1mixture of hexane/CH₂ Cl₂). 4.20 g of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol[2,3,b]furanyl)benzoic acid which melts at 184°-185° C. are recovered.

EXAMPLE 2 Preparation ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3,b]furanyl)benzoic acid

3.80 g (10.4 mmoles) of the ester obtained in 1(d) above are treated atreflux for 4 hours with 200 ml of 2N methanolic soda. The methanol isevaporated and the remainder is taken up in water and acidified withconcentrated HCl. The reaction mixture is extracted with ether and theorganic phase is decanted, dried on MgSO₄ and the solvents areevaporated. The residue is recrystallized in a 2/1 mixture ofdiisopropyl ether and ethyl acetate. 3.50 g (97%) ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3,b]furanyl)benzoic acid which melts at 307°-312° C. are recovered.

EXAMPLE 3 Methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid (a)2-N,N-dimethylthiocarbamoyloxy)-3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene

In a round bottom flask there are introduced 1.7 g (57 mmoles) of sodiumhydride (80% in oil) and 50 ml of dimethylformamide. There is slowlyadded a solution of 10.3 g (47 mmoles) of3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol in 100 ml ofDMF and the reaction mixture is stirred until the cessation of gasevolvement. There are then added 8.1 g (66 mmoles) ofdimethylthio-carbamoylchloride in 100 ml of DMF and the reaction mixtureis stirred for 4 hours at ambient temperature. The reaction mixture ispoured into water and extracted with ethylether. The organic phase isdecanted, washed with water, dried on MgSO₄ and the solvent evaporated.The residue is purified by chromatography on a silica column (eluant:20/80 mixture of CH₂ Cl₂ /hexane). 13.2 g (92%) of2-(N,N-dimethylthiocarbamoyloxy)-3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene which melts at 102°-103° C. are recovered.

(b) 2-N,N-dimethylcarbamoylthio)-3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphthalene

13 g (42.5 mmoles) of the compound obtained in 3(a) above are heatedunder nitrogen at 280° C. After cooling, the residue is passed through asilica column (eluant: 70/30 mixture of hexane/CH₂ Cl₂).

10.2 g (79%) of2-(N,N-dimethylcarbamoylthio-3-methyl-5,6,7,8-tetahydro-5,5,8,8-tetramethylnaphthalene which melts at 142°-143° C. are obtained.

(c) 3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-thionaphthol

9.2 g (30 mmoles) of the product obtained in 3(b) above are treated atreflux with 200 ml of 2N methanolic soda for 2 hours. The solvents areevaporated and the remainder is taken up in water, acidified to pH 0(concentrated HCl) and extracted with ether. The organic phase isdecanted, dried on magnesium sulfate and the solvents are evaporated.6.9 g (98%) of3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-thionaphthol whichmelts at 91°-92° C. are obtained.

(d) Methyl ester ofp-(3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylthio)carbonyl benzoic acid

In a round bottom flask there are introduced 5.9 g (33 mmoles) of themonomethyl ester of terephthalic acid and 50 ml of THF. There are thenadded, by small portions, 5.3 g (33 mmoles) of 1,1'-carbonyldiimidazole.The reaction mixture is stirred until the cessation of gaseousemissions. There are then added 7 g (30 mmoles) of the compound obtainedin 3(c) above in 50 ml of THF and the mixture is stirred for 7 hours atambient temperature.

The reaction mixture is poured into water, extracted with ether andwashed with a saturated solution of sodium bicarbonate. The organicphase is decanted, dried on MgSO₄ and the solvent evaporated. Theresidue is recrystallized in isooctane to give 9.5 g (81%) of the methylester ofp-(3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylthio)carbonyl benzoic acid which melts at 105°-106° C.

(e) Methyl ester ofp-(3-bromomethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylthio)carbonyl benzoic acid

9.26 g (23 mmoles) of the compound prepared in 3(d) above are heated atreflux in 150 ml of carbon tetrachloride containing 50 mg of benzoyl.peroxide. There are then added, in small amounts 4.16 g (23 mmoles) ofN-bromosuccinimide and once the addition has ended, reflux is maintainedfor 12 hours. The solvent is evaporated and the residue is purified bychromatography on a silica column (eluant: 1/1 mixture of CH₂ Cl₂/hexane). 10.8 g of a mixture of the expected monobromo derivative (85%)and nonbrominated and dibrominated (15%) are obtained. (Dosage effectedby comparing the integration of signals in NMR of the proton of themethyl, bromomethyl and dibromomethyl groups in the compounds of themixture). The mixture is used as such for the following synthesis.

(f) Methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid

In a round bottom flask, there are introduced 10.5 g of the precedingmixture, 6 g (23 mmoles) of triphenylphosphine and 100 ml of THF. Thereaction mixture is heated at reflux for 4 hours and cooled to 10° C.3.5 ml (23 mmoles) of DBU are added and the reaction mixture is stirredfor 4 hours at ambient temperature, poured into water and extracted withether. The organic phase is decanted, dried on MgSO₄ and the solventevaporated. The residue is purified by chromatograph on a silica column(eluant: 80/20 mixture of hexane/dichloromethane) 6.6 g of the methylester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid which melts at 186°-187° C. are obtained.

EXAMPLE 4 Preparation ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid

5 g (13 mmoles) of the ester obtained in 3(f) are treated with 200 ml of2N methanolic soda. The reaction mixture is heated at reflux for 2hours, evaporated to dryness, taken up in water, acidified to pH=1 withconcentrated HCl and extracted with ether. The organic phase isdecanted, dried on MgSO₄ and the solvent evaporated. The residue isrecrystallized in a 2/1 mixture of isopropylether/ethyl acetate. 4.6 g(96%) ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-b]thienyl)benzoic acid which melts at 291°-292° C. are obtained.

EXAMPLE 5 Preparation ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl) benzoicacid (a) 2-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphthanlene

In a round bottom flask there are introduced 64 ml (600 mmoles) oftoluene and 36.6 g (200 mmoles) of 2,5-dichloro-2,5dimethyl hexane. Thereaction mixture is cooled to 0° C. and there are added, by smallamounts, 4.1 g (30 mmoles) of aluminum chloride. The reaction mixture isstirred for 1 hour at ambient temperature, poured into water andextracted with CH₂ Cl₂. The organic phase is decanted, dried onmagnesium sulfate and evaporated. The resulting oil is purified bydistillation. 39.4 g (98%) of2-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphthalene which boilsat 68° C. (under 1 mm of mercury) are obtained.

(b) 2-methyl-3-nitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphthalene

50 g (250 mmoles) of 2-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene are dissolved in 200 ml of acetic anhydride. The solution iscooled to 0° C. and there is slowly added a solution of 10.5 ml (250mmoles) of nitric acid, 20 ml of acetic acid and 20 ml of aceticanhydride, while maintaining the temperature between 0° and 5° C. Thereaction mixture is then stirred for 1 hour at ambient temperature,poured into ice water and filtered. The resulting solid is washed withwater. The solid is dissolved in methylene chloride, washed with waterand then with a saturated solution of sodium bicarbonate, dried on MgSO₄and evaporated. 45.8 g (74%) of2-methyl-3-nitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphthalenewhich melts at 143°-144° C. are obtained.

(c) 3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylamine

24.7 g (100 mmoles) of the nitro derivative obtained in 5(b) aredissolved in 400 ml of ethanol. To this solution there are added 33.6 g(600 mmoles) of powdered iron and then, slowly, 38 ml of concentratedHCl. The reaction mixture is heated at reflux for 1 hour and evaporatedto dryness. The residue is taken up in water to which is added withcaution an excess of sodium bicarbonate. The mixture is then extractedwith ether, filtered and the filtrate is recovered, dried on MgSO₄ andevaporated. 21.2 g (98%) of3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylamine whichmelts at 94°-95° C. are obtained.

(d) Methyl ester ofp-[(3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid

8.1 g (45 mmoles) of methyl monoterephthalate are dissolved in 100 ml ofTHF. To this solution there are added, by small quantities, 8 g (45mmoles) of 1,1'-carbonyldiimidazole. The mixture is stirred until thegaseous emissions have ceased and then there is slowly added a solutionof 9.8 g (45 mmoles) of the amine obtained in 5(c) above in 50 ml ofTHF. The reaction mixture is stirred for 2 hours at ambient temperature,poured into water and extracted with CH₂ Cl₂. The organic phase isdecanted, dried on MgSO₄ and evaporated.

The residue is recrystallized in isopropylether to give 14.6 g (86%) ofthe methyl ester ofp-[(3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid which melts at 169°-170° C.

(e) Methyl ester ofp-[(N-tert.butoxycarbonyl-3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylcarbamoyl)]benzoic acid

In a round bottom flask there are introduced 1.2 g (40.5 mmoles) ofsodium hydride (80% in oil), 20 ml of DMF and 30 ml of THF. There isslowly added a solution of 13.9 g (37 mmoles) of the ester obtained in5(d) in 60 ml of THF. The reaction mixture is stirred until the gaseousemissions have ceased. There are then added 8.8 g (40.5 mmoles) ofdi-tert.butyl dicarbonate in 100 ml of THF and the mixture is stirred atambient temperature for 4 hours. The reaction mixture is poured intowater and extracted with ethyl ether. The organic phase is decanted,washed with water, dried on MgSO₄ and evaporated. The residue ispurified by chromatography on a silica column (eluant: 7/3 mixture ofdichloromethane/hexane). 14.1 g (82%) of the methyl ester ofp-[(N-tert.butoxycarbonyl-3-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylcarbamoyl)] benzoic acid which melts at 176°-177° C. areobtained.

(f) Methyl ester ofp-(3-bromomethyl-N-tert.butoxycarbonyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylcarbamoyl)benzoic acid

13.25 g (27.6 mmoles) of the ester obtained in 5(e) are placed in around bottom flask. There are added 150 ml of carbon tetrachloride and50 mg of benzoyl peroxide The mixture is heated at reflux and there areintroduced, in small amounts, 4.9 g (27.6 mmoles) of N-bromosuccinimide.Reflux is maintained for 12 hours. The solvent is evaporated and theresidue is purified by chromatography on silica, by eluting with a 1/1mixture of dichloromethane and hexane. 14.2 g are obtained of a mixturecontaining about 85% of the expected monobromo derivative and 15% of amixture of dibromonated product and starting product (these proportionsbeing estimated by NMR, in a manner analogous to that of Example 3(e).The mixture is used as such in the following synthesis.

(g) Methyl ester ofp-(N-tert.butoxycarbonyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indoly) benzoic acid

Into a round bottom flask there are introduced 13.9 g of the mixtureobtained in 5(f), 6.7 g (25.5 mmmoles) of triphenyl phosphine and 100 mlof THF. The mixture is heated at reflux for 8 hours and then cooled to5° C. There are then slowly added 3.8 ml (25.5 mmoles) of DBU. Thereaction mixture is stirred at ambient temperature for 2 hours, pouredinto water and extracted with ether. The organic phase is decanted,dried on MgSO₄ and evaporated. The residue is purified by chromatographyon a silica column (eluant: 20/80 mixture of CH₂ Cl₂ /hexane). 6.7 g(69%) of the methyl ester ofp-(N-tert.butoxycarbonyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl)benzoic acid which melts at 145°-146° C. are obtained.

(h) p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl)benzoic acid

6.4 g (14 mmoles) of the ester obtained in 5(g) are treated at refluxfor 4 hours with 100 ml of 2N methanolic soda. The solvent is evaporatedand the remainder is taken up in water, acidifying the aqueous phase topH 5 with HCl and extracted with ethyl ether. The organic phase isdecanted, dried on MgSO₄ and evaporated. The residue is triturated in100 ml of hexane. 4.3 g (40%) ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl) benzoicacid which melts at 294°-296° C. are obtained.

EXAMPLE 6 Preparation of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl) benzoicacid

2.3 g (6.6 mmoles) ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl) benzoicacid are introduced into a round bottom flask containing 150 ml ofmethanol. There are slowly added 2 ml of concentrated sulfuric acid andthe reaction mixture is heated at reflux for 4 hours. The reactionmixture is then evaporated to dryness and the remainder is taken up inwater, alkalinized with sodium bicarbonate and extracted with methylenechloride. The organic phase is decanted, dried on MgSO₄ and evaporated.2.3 g (96%) of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-1H-benz[f]indolyl) benzoicacid which melts at 212°-213° C. are obtained.

EXAMPLE 7 Preparation of the methyl ester ofp-(1-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-benz[f]indolyl)benzoic acid

180 mg (5.1 mmoles) of sodium hydride (80% in oil are suspended in 20 mlof DMF. There are slowly added 1.8 g (5 mmoles) of the ester prepared inExample 6, dissolved in 5 ml of THF. The reaction mixture is stirreduntil the evolution of gas ceases. There are then added 0.4 ml (6.4mmoles) of methyl iodide and the reaction mixture is stirred for 2 hoursat ambient temperature. The reaction mixture is poured into water andextracted with CH₂ Cl₂. The organic phase is decanted dried on MgSO₄ andevaporated. The residue is purified by chromatography on a silica columnby eluting with a 4/1 mixture of dichloromethane and hexane. Afterevaporation of the solvents, 1.4 g (78%) of the methyl ester ofp-(1-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-benz[f]indolyl)benzoic acid which melts at 147°-148° C. are obtained.

EXAMPLE 8 Preparation ofp-(1-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl- 2-benz[f]indolyl)benzoic acid

1.2 g (3.2 mmoles) of the ester obtained in Example 7 are treated atreflux for 2 hours with 100 ml of 2N methanolic soda. The mixture isheated for 2 hours at reflux evaporated to dryness, taken up in water,the aqueous phase is acidified to pH 5 with HCl and extracted withether. The organic phase is decanted, dried on MgSO₄ and evaporated. Theresidue is pulverized in 100 ml of hexane and then filtered togive 1.13g (97%) ofp-(1-methyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-benz[f]indolyl)benzoic acid which melts at 288°-289° C.

EXAMPLE 9 Preparation of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (a) 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol.

54.9 g (300 mmoles) of 2,5-dichloro-2,5-dimethyl hexane are dissolved indichloromethane (500 ml). There is then added phenol (28.2 g - 300mmoles) and then aluminum chloride (8.0 g - 60 mmoles). The mixture isvigorously stirred for 16 hours. Water is then added (200 ml) and themixture is extracted with dichloromethane (3×200 ml). The organic phaseis washed with a saturated solution of sodium bicarbonate and then witha saturated solution of sodium chloride. It is then dried on magnesiumsulfate, filtered and the solvents are evaporated.

The resulting solid is washed with a mixture composed of 80% hexane and20% dichloromethane, (200 ml), yielding5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol: 43.5 g (71%), whichmelts at 142° C.

(b) 3-nitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol

5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol (42.86 g-210 mmoles)is dissolved in acetic anhydride (420 ml).

The solution is cooled to -10° C. and 40 ml of acetic acid are added.There is then added fuming nitric acid (8.7 ml - 210 mmoles) in solutionin a mixture of acetic anhydride (40 ml) and acetic acid (40 ml). Thereaction mixture is stirred for one hour at ambient temperature.

The reaction mixture is then poured into water (1 liter) plus ice. Theprecipitate that forms is filtered, washed with water, taken up indichloromethane (3×200 ml). The organic phase is washed with a saturatedsolution of sodium bicarbonate and then with water. It is dried onmagnesium sulfate, filtered and the solvent evaporated.

The resulting solid is purified by chromatography on silica and elutedwith a 50/50 mixture of dichloromethane and hexane.

19.6 g (37%) of3-nitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol which melts at139° C. are obtained.

(c) 3-amino-5,6,7,8-tetramethyl-2-naphthol.

3-nitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol (35.3 g - 14mmoles) is mixed with methanol (1 liter).

To this mixture there are added about 2 spatulas full of Raney nickelwashed with methanol and the mixture is hydrogenated until the end ofabsorption.

The precipitate that forms is dissolved by the addition ofdichloromethane (1 liter).

The catalyst is filtered and the solvents are evaporated.

The resulting crystals are washed with hexane (2 liters) and thenfiltered. 30.9 g (99%) of3-amino-5,5,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol which melts at225° C. are obtained.

(d) Methyl ester ofp-[(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl(carbamoyl]benzoic acid

17.5 g (80 mmoles) of3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol are mixed withethyl ether (400 ml). Triethylamine (11.1 ml - 80 mmoles) is added andthen slowly 15.81 g (80 mmoles) of p-methoxy carbonyl benzoyl chloridein solution in ether (200 ml).

The reaction mixture is stirred for 2 hours at ambient temperature andthen poured into a mixtureof water (500 ml) and dichloromethane (300ml).

The aqueous phase is extracted with dichloromethane (2×300 ml) and theorganic phase is washed with a saturated solution of sodium chloride,dried on magnesium sulfate, filtered and the solvent evaporated.

The resulting solid is purified by column chromatography and eluted withdichloromethane.

24.38 g (80%) of the methyl ester ofp-[(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoicacid which melts at 200°-210° C. are obtained.

(e) methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid

The methyl ester ofp-[(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid (23.25 g - 61 mmoles) is mixed with xylene (600ml). There are added 11.6 g (61 mmoles) of p-toluene sulfonic acid andthe mixture is heated at reflux, with stirring, for 3 hours. The xyleneis evaporated and there are added water (500 ml) and somedichloromethane. There are then added to the aqueous phase about 300 mlof a saturated solution of sodium bicarbonate and the mixture isextracted with dichloromethane (3×300 ml). The organic phase is thenwashed with a saturated solution of sodium bicarbonate and then withwater.

The organic phase is dried on magnesium sulfate, filtered and thesolvents are evaporated.

The resulting solid is purified by column chromatography and eluted witha mixture of 80% dichloromehtane and 20 % hexane.

The methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (12.25 g - 54%) which melts at 174° C. is obtained.

EXAMPLE 10 Preparation ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid

The methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (7.27 g - 20 mmoles) is mixed with methanol (400 ml). Thereis then added 5N soda (40 ml) and the mixture is heated at reflux for 1hour.

The methanol is evaporated and ethyl ether (300 ml) and 4N HCl (200 ml)are added. The aqueous phase is extracted with ether (2×300 ml) and theorganic phase is washed twice with water and once with a saturatedsolution of sodium chloride.

The organic phase is dried on magnesium sulfate, filtered and thesolvent evaporated.

The resulting solid is taken up in hexane (300 ml), filtered and dried.7.00 g (100%) of p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtho[2,3-d]oxazolyl) benzoic acid which melts at 290° C. are obtained.

EXAMPLE 11 Preparation ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzyl alcohol

The methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (2.64 g - 7.26 mmoles) is dissolved in dry tetrahydrofuran(50 ml). This solution is slowly (474 mg - 11.9 mmoles) in suspension indry tetrahydrofuran (50 ml).

The reaction mixture is heated at reflux for 5 hours, cooled to 0° C.,then hydrolyzed by the slow addition of 30 ml of a solution of thedouble tartrate of sodium and potassium.

The solvent is evaporated, 300 ml of water are added and the product isextracted with ether (6×200 ml). The organic phase is washed with asaturated solution of sodium chloride and then dried on magnesiumsulfate. After evaporation of the solvent, the product is recrystallizedin acetonitrile. 216 g (89%) ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzyl alcohol which melts at 200° C. are obtained.

EXAMPLE 12 Preparation ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic aldehyde

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzyl alcohol (1.24 g - 3.7 mmoles) is dissolved in dichloromethane (30ml). There is then added pyridinium chlorochromate (1.20 g - 5.54mmoles) in solution in 8 ml of dichloromethane. The reaction mixture isstirred for 2 hours at ambient temperature and the solvent is thenevaporated.

The product is purified by column chromatography and eluted with amixture composed of 80% ether and 20% hexane. The solvents areevaporated and the resulting solid is taken up in hexane, filtered anddried. 920 mg (75%) of p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl) benzoic aldehyde which melts at 179° C. areobtained.

EXAMPLE 13 Preparation of the ethylamide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (a)p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid chloride

p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (4.57 g - 13.1 mmoles) is suspended in dichloromethane (200ml). There is then slowly added dicyclohexylamine (2.37 g - 13.1 mmoles)and the dichloromethane is then evaporated.

The resulting solid is taken up in ether (500 ml), filtered and thendried, yielding the dicyclohexylamine salt op-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (6.94 g - 100%).

The above salt is dissolved in dichloromethane (100 ml). The resultingsolution is cooled to 0° C. and there is then slowly addedthionychloride (1.55 g 13.1 mmoles).

The reaction mixture is stirred for 2 hours at ambient temperature. Theformed dicyclohexylamine hydrochloride is filtered and thedichloromethane is evaporated.

The resulting crude acid chloride is used as such for the followingsynthesis.

(b) ethylamide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid

Ethylamine (216 mg-4.8 mmoles) is dissolved in dry tetrahydrofuran (25ml). There are added successively triethylamine (485 mg-4.8 mmoles) andthen slowly the acid chloride obtained in Example 12(a) (1.6 g - 4.4mmoles) in solution in dry tetrahydrofuran (25 ml).

The reaction mixture is stirred for 1 hour at ambient temperature andthen poured into 2N HCl (200 ml). The product is extracted with ether(3×100 ml), and then the organic phase is washed with water (3 times),then by a saturated solution of sodium chloride and dried on magnesiumsulfate

The solution is filtered and the solvents are evaporated The resultingsolid is taken up in hexane (300 ml), filtered and dried. The ethylamideof p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (1.07 g - 65%) which melts at 174° C. is obtained.

EXAMPLE 14 Preparation of the morpholide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid

Morpholine (417 mg - 4 8 mmoles) is dissolved in dry tetrahydrofuran (25ml) There are successively added triethylamine (485 mg - 4.8 mmoles) andthen slowlyp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid chloride (1.6 g- 4.4 mmoles) in solution in drytetrahydrofuran (25 ml).

The reaction mixture is stirred for 2 hours at ambient temperature andthen poured into 4N HCl (200 ml).

The product is extracted with ether (3×200 ml), the organic phase iswashed with water (3 times) and then with a saturated solution of sodiumchloride and finally dried on magnesium sulfate.

The solution is filtered and the solvents evaporated. The product ispurified by chromatography on silica, eluted with a mixture of 50%dichloromethane, 20% ether and 30% hexane.

The solvents are evaporated and the resulting solid is taken up inhexane (300 ml).

The morpholide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid (1.13 g - 62%) which melts at 193° C. is obtained.

EXAMPLE 15 Preparation of the 2-hydroxyethyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid

Ethylene glycol (298 mg - 4.8 mmoles) is dissolved in drydichloromethane (25 ml). There are successively added pyridine (380 mg -4.8 mmoles) and then slowlyp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid chloride (1.6 g - 4.4 mmoles) in solution in drydichloromethane (25 ml).

The reaction mixture is stirred for 2 hours at ambient temperature andthen poured into 200 ml of 4N HCl.

The product is extracted with ether (3×200 ml). The organic phase iswashed with water (3 times) and then with a saturated solution of sodiumchloride and finally dried on magnesium sulfate.

The solution is filtered and the solvents are evaporated. The product ispurified by chromatography on silica, eluted by a mixture of 70%dichloromethane and 30% ether.

875 mg (51%) of the 2-hydroxyethyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth [2,3-d]oxazolyl)benzoic acid which melts at 144° C. are obtained.

EXAMPLE 16 Preparation of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]imidazolyl)benzoic acid (a) 2,3-dinitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene

91.5 g (490 mmoles) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene are dissolved in concentrated sulfuric acid (365 ml). Thesolution is cooled to 0° C. and there is added, with mechanicalstirring, fum9ing nitric acid (365 ml).

The reaction mixtures is stirred for 2 hours at ambient temperature andthen poured over ice.

The product is extracted with ethyl ether (3×1 liter). The organic phaseis neutarlized by the addition of solid sodium bicarbonate (+300 ml ofwater), decanted and dried on magnesium sulfate.

The organic phase is filtered, the solvent is evaporated and theresulting solid is recrystralized in cyclohexane.

80.19 g (59%) of 2,3-dinitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene, which melts at 200° C. are obtained.

(b)2,3-diamino-5,6,7,8-tetarhydro-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene

36.12 g (130 mmoles) of2,3-d(nitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphalene aredissolved in 1 liter of methanol. There are added about 2 spatulas-fullof Raney nickel and the mixture is washed with methanol and hydrogenateduntil the end of absorption The catalyst is filtered, the solvents areevaporated and the resulting solid is washed with about 300 ml ofhexane.

14.49 g (51%) of 2,3-diamino-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene which melts at 185° C. are obtained.

(c) methyl ester ofp-[(3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid

2,3-diamino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl naphthalene (6.55 g -30 mmoles) is mixed with methyl ether (170 ml); there are added to themixture triethylamine (4.2 m-30 mmoles) and then, slowly, methylp-chloroformyl benzoate (5.96 g - 30 mmoles) in solution in ether (70ml).

The reaction mixture is stirred for 2 hours at ambient temperature andit is then poured into a mixtureof water (400 ml) and dichloromethane(400 ml).

The organic phase is washed with a saturated solution of sodiumbicarbonate, then with a saturated solution of sodium chloride, dried onmagnesium sulfate, filtered and the solvents evaporated.

The resulting solid is purified by column chromatography, eluted with asystem composed of 10% ethyl ether and 90% dichloromethane.

3.73 g of the methyl ester ofp-[3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) carbamoyl]benzoic acid in the form of a white solid are obtained.

(d) methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]imidazolylbenzoic acid

3.65 g (9.6 mmoles of the methyl esterp-[(3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl(carbamoyl]benzoic acid are dissolved in xylene (200 ml) To the solution there isadded p-toluene sulfonic acid monohydrate (1.82 g - 9.6 mmoles) and themixture is heated at reflux, with stirring, for 1 hour. The xylene isevaporated and there are added 300 ml of water and 300 ml of a saturatedsolution of sodium bicarbonate. The aqueous phase is extracted withdichloromethane (3+300 ml) and the organic phase is washed with asaturated solution of sodium chloride, dried on magnesium sulfate,filtered and the solvents evaporated. The resulting solid is purified bycolumn chromatography and eluted with a mixture composed of 95%dichloromethane and 5% ethyl ether

2.7 g (78%) of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth [2,3-d]imidazolyl)benzoic acid which melts at 270°-275° C. (decomposition) are obtained.

EXAMPLE 17 Preparation ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]imidazolyl)benzoic acid

1.52 g (4.2 mmoles) of the methyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth [2,3-d]imidazolyl)benzoic acid are mixed with 300 ml of methanol. There is added to themixture 5N soda solution (8.4 ml) and it is heated at reflux for 24hours.

The methanol is evaporated and the pH is the adjusted too 5 by theaddition 1N HCl.

The product is extracted with ether (5×400 ml), and the organic phase iswashed with water (2×500 ml) and then with a saturated solution ofsodium chloride (2×300 ml).

The organic phase is dried on magnesium sulfate, filtered and thesolvents are evaporated. The resulting solid is taken up in 300 ml ofhexane, filtered and oven dried.

920 mg (63%) ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3d]imidazolyl)benzoic acid, which melts at 250° C. (decomposition), are obtained.

EXAMPLE 18 Preparation of2-(4-methyl)phenyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphth[2,3-d]imidazole (a)N-(3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-4-methylbenzamide

4 g (18 mmoles) of 2,3-diamino-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene are suspended in 100 ml of ether. There are added to thesuspension triethylamine (2.55 ml - 18.3 mmoles) and then 2.83 g (18.3mmoles) of 4-methyl benzoyl chloride in solution in 50 ml of ether.

The reaction mixture is stirred for 1 hour and there are then added 300ml of dichloromethane. The aqueous phase is extracted withdichloromethane (2×300 ml) and the organic phase is washed with asaturated solution of sodium chloride

The organic phase is dried on magnesium sulfate, filtered and thesolvents are evaporated.

The product is purified by column chromatography and eluted with amixture of 10% ether and 90% dichloromethane.

2.75 g (45%) ofN-(3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-4-methylbenzamide,which melts at 180° C. are obtained.

(b)2-(4-methyl)phenyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphth-[2,3-d]imidazole

2.72 g (8.1 mmoles) of N-(3-amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthyl)-4-methylbenzamide are mixed with 150 ml of xylene. There areadded to the mixture 1.54 g (8.1 mmoles) of p-toluene sulfonic acid andthe mixture is heated at reflux for 2 hours. The xylene is evaporatedand there are added 300 ml of water and 300 ml of dichloromethane.

The aqueous phase is extracted with dichlormethane. The organic phase iswashed with a saturated solution of sodium chloride, dried on magnesiumsulfate, filtered and the solvents are evaporated.

The product is purified by column chromatography and eluted with amixture of 10% ether and 90% hexane.

1.78 g (69%) of2-(4-methyl)phenyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphth[2,3-d]imidazoleare obtained.

EXAMPLES OF COMPOSITIONS A. Oral Compositions

    ______________________________________                                        Example I - 0.2 g tablet                                                      ______________________________________                                        p-(5,6,7,8-tetrahydro-5,5,8,8-                                                                       0.0001  g                                              tetramethyl-2-naphtho [2,3-b]                                                 thienyl) benzoic acid                                                         Dicalcium phosphate    0.020   g                                              Silica                 0.020   g                                              Lactose                0.030   g                                              Talc                   0.040   g                                              Magnesium stearate     0.005   g                                              Starch, sufficient amount for                                                                        0.200   g                                              ______________________________________                                    

In this Example, the active compound can be replaced by its methylester.

    ______________________________________                                        Example II - 0.4 g capsule                                                    ______________________________________                                        p-(5,6,7,8-tetrahydro-5,5,8,8-                                                                       0.0002  g                                              tetramethyl-naphtho[2,3-b]                                                    furan-2-yl benzoic acid                                                       Glycerine              0.200   g                                              Sucrose                0.0050  g                                              Polyethylene glycol 400                                                                              0.050   g                                              Purified water, sufficient                                                                           0.400   g                                              amount for                                                                    ______________________________________                                    

The capsule is made of gelatin, glycerine, titanium dioxide and water.

    ______________________________________                                        Example III - 0.5 g gelule                                                    ______________________________________                                        Morpholide of p-(5,6,7,8-tetrahydro-                                                                  0.0005  g                                             5,5,8,8-tetramethyl-2-naphth                                                  [2,3-d]oxazolyl) benzoic acid                                                 Cornstarch              0.150   g                                             Magnesium stearate      0.250   g                                             Sucrose, sufficient amount for                                                                        0.500   g                                             ______________________________________                                    

The above powder is packaged in a gelule composed of gelatin and TiO₂.

B. Topical Compositions

    ______________________________________                                        Example IV - Ointment                                                         ______________________________________                                        p-(5,6,7,8-tetrahydro-5,5,8,8-                                                                       0.0001  g                                              tetramethyl-2-naphth[2,3-d]                                                   oxazoyl) benzoic acid                                                         Stearyl alcohol        3.000   g                                              Lanolin                5.000   g                                              Petrolatum             15.000  g                                              Distilled water, sufficient                                                                          100.000 g                                              amount for                                                                    ______________________________________                                    

    ______________________________________                                        Example V - Ointment                                                          ______________________________________                                        p-(5,6,7,8-tetrahydro-5,5,8,8-                                                                       0.0005  g                                              tetramethyl-2-1H-benz[f]                                                      indolyl)benzoic acid                                                          Stearyl alcohol        3.000   g                                              Lanolin                5.000   g                                              Petrolatum             15.000  g                                              Distilled water, sufficient                                                                          100.000 g                                              amount for                                                                    ______________________________________                                    

    ______________________________________                                        Example VI - Gel                                                              ______________________________________                                        Methyl ester of p-(5,6,7,8-                                                                           0.0005  g                                             tetrahydro-5,5,8,8-tetramethyl-                                               2-naphtho[2,3-b]furan-2-yl)                                                   benzoic acid                                                                  Hydroxypropyl cellulose, sold by                                                                      2.000   g                                             Hercules under the trade name                                                 "Klucel HF"                                                                   Water/ethanol, 50:50, sufficient                                                                      100.000 g                                             amount for                                                                    ______________________________________                                    

What is claimed is:
 1. A polycyclic heterocyclic compound having theformula ##STR12## wherein n is 1 or 2,R₁ represents (i) .[.hydrogen.]..Iadd.lower alkyl.Iaddend.,(ii) --CH₂ OH or (iii) ##STR13## R₂represents (a) hydrogen, (b) ##STR14## or (c) --OR₃ wherein R₃represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl,polyhydroxyalkyl, phenyl, phenyl substituted by halogen, hydroxy, nitroor lower alkyl, benzyl, phenethyl, a sugar radical selected from thegroup consisting of glucose, mannose, erythrose and galactose, or##STR15## wherein p is 1, 2 or 3 and r' and r" represents hydrogen,lower alkyl, monohydroxyalkyl, polyhydroxyalkyl, phenyl, phenylsubstituted by halogen, hydroxy, nitro or lower alkyl, aminated sugarradical selected from the group consisting of glucosamine, galactosamineand mannosamine, or r' and r" taken together form a heterocycle selectedfrom the group consisting of piperidino, piperazino, morpholino,pyrrolidino and 4-(2'-hydroxyethyl) piperazino, X represents oxygen, Yrepresents a nitrogen atom, or a salt of said polycyclic heterocycliccompound of formula I.
 2. A polycyclic heterocyclic compound having theformula ##STR16## wherein n is 1 or 2,R₁ represents (i) .[.hydrogen.]..Iadd.lower alkyl.Iaddend., (ii) --CH₂ OH or (iii) ##STR17## R₂represents (a) hydrogen, (b) ##STR18## or (c) --OR₃ wherein R₃represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl,polyhydroxyalkyl, phenyl, phenyl substituted by halogen, hydroxy, nitroor lower alkyl, benzyl, phenethyl, or ##STR19## wherein p is 1, 2 or 3and r' and r" represent hydrogen, lower alkyl, monohydroxyalkyl,polyhydroxyalkyl, phenyl, phenyl substituted by halogen, hydroxy, nitroor lower alkyl, or r' and r" taken together form a heterocycle selectedfrom the group consisting of piperidino, piperazino, morpholino,pyrrolidino and 4-(2'-hydroxyethyl( piperazino, X represents oxygen, Yrepresents a nitrogen atom, or a salt of said polycyclic heterocycliccompound of formula I.
 3. The compound of claim 1 wherein said loweralkyl has 1-4 carbon atoms.
 4. The compound of claim 2 wherein saidlower alkyl is methyl, ethyl, isopropyl, butyl or tert.butyl.
 5. Thecompound of claim 1 wherein said monohydroxyalkyl has 2-4 carbon atoms.6. The compound of claim 4 wherein said monohydroxyalkyl is2-hydroxyethyl, 2-hydroxypropyl or 2'-hydroxy-2-ethoxyethyl.
 7. Thecompound of claim 1 wherein said polyhydroxyalkyl has 3-6 carbon atomsand 2-5 hydroxyl groups.
 8. The compound of claim 6 wherein saidpolyhydroxyalkyl is 2,3-dihydroxypropyl,2,3,4-trihydroxybutyl,2,3,4,5-tetrahydroxypentyl or the residue ofpentacrythritol.
 9. The compound of claim 1 having the formula ##STR20##wherein R₃ represents hydrogen or lower alkyl,X represents oxygen, Yrepresents a nitrogen atom, R₄ represents hydrogen or methyl.
 10. Thecompound of claim 2 selected from the group consisting ofmethyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid, p-(5,6,7,8-tetrahydro-b5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl) benzoic acid,p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzyl alcohol,p-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic aldehyde, ethylamide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3d]oxazolyl)benzoic acid, morpholide ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid, and 2-hydroxyethyl ester ofp-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphth[2,3-d]oxazolyl)benzoic acid.
 11. A pharmaceutical composition for the treatment of adermotologic, rheumatoidal, respiratory or opthalmologic disordercontaining in a vehicle suitable for enteral, parenteral, rectal,topical or ocular administration an effective amount of a compound offormula I of claim
 1. 12. The pharmaceutical composition of claim 11 ina vehicle for topical application, said composition containing saidcompound to 0.01 percent by weight based on the total weight of saidcomposition.